Marea re­ports ear­ly Phase 2 da­ta for cho­les­terol-low­er­ing drug it li­censed from No­var­tis

Marea Ther­a­peu­tics on Fri­day post­ed some en­cour­ag­ing re­sults with its lead pro­gram, a triglyc­eride-low­er­ing med­i­cine for car­dio­vas­cu­lar dis­ease, that could give an in­di­ca­tion of whether …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER